Home › Funds › Avoro Capital Advisors LLC › VRDN

Avoro Capital Advisors LLC position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Avoro Capital Advisors LLC reported holding 2,500,000 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$51.5M, representing 0.53% of its reported portfolio and ranking #20 among its reported holdings. Avoro Capital Advisors LLC has disclosed VRDN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)2.50M sh
Reported value held$51.48M
Portfolio Weight0.53%
First reportedQ4 2025
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Avoro Capital Advisors LLC's VRDN position evolved

Avoro Capital Advisors LLC first disclosed a stake in VRDN in Q4 2025 at 1,500,000 shares (US$46.7M). The position peaked in Q3 2026 at 2,500,000 shares, worth US$51.5M. Across 4 filings, Avoro Capital Advisors LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,500,000 shares valued at US$51.5M. Notable position changes include a 67% increase in Q2 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.50M $46.68M New
Q1 2026 1.50M $29.34M Hold
Q2 2026 2.50M $45.92M Add
Q3 2026 2.50M $51.48M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Avoro Capital Advisors LLC held VRDN?

Avoro Capital Advisors LLC has disclosed VRDN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Avoro Capital Advisors LLC's current position in VRDN?

As of Q3 2026, Avoro Capital Advisors LLC holds 2.50M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $51.48M, representing 0.53% of its reported portfolio and ranking #20.

Has Avoro Capital Advisors LLC been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC held unchanged its position in VRDN. The position peaked in Q3 2026 at 2.50M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.